Patents by Inventor Chawita Netirojjanakul

Chawita Netirojjanakul has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RNAi constructs for inhibiting ASGR1 expression and methods of use thereof
    Patent number: 11732266
    Abstract: The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: August 22, 2023
    Assignee: AMGEN INC.
    Inventors: Michael Ollmann, Yang Li, Jun Zhang, Oliver Homann, Leslie P. Miranda, Justin K. Murray, Bin Wu, Oh Kyu Yoon, John Gordon Allen, Chawita Netirojjanakul, Yuan Cheng
  • METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING GLP-1 RECEPTOR AGONISTS CONJUGATED TO ANTAGONISTS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR)
    Publication number: 20210154318
    Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.
    Type: Application
    Filed: January 15, 2021
    Publication date: May 27, 2021
    Inventors: Yuan CHENG, Chawita NETIROJJANAKUL, Jerry Ryan HOLDER, Bin WU, James R. FALSEY, Bradley J. HERBERICH, Kelvin SHAM, Leslie P. MIRANDA, Shu-Chen LU, Murielle VENIENT-ELLISON, Shanaka STANISLAUS, Junming YIE, Jing XU
  • RNAi Constructs for Inhibiting ASGR1 Expression and Methods of Use Thereof
    Publication number: 20210108212
    Abstract: The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.
    Type: Application
    Filed: October 26, 2020
    Publication date: April 15, 2021
    Applicant: AMGEN INC.
    Inventors: Michael OLLMANN, Yang LI, Jun ZHANG, Kaustav BISWAS, Oliver HOMANN, Leslie P. MIRANDA, Justin K. MURRAY, Bin WU, Oh Kyu YOON, John Gordon ALLEN, Chawita NETIROJJANAKUL, Yuan CHENG
  • Method of treating or ameliorating metabolic disorders using GLP-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (GIPR)
    Patent number: 10905772
    Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: February 2, 2021
    Assignee: Amgen Inc.
    Inventors: Yuan Cheng, Chawita Netirojjanakul, Jerry Ryan Holder, Bin Wu, James R. Falsey, Bradley J. Herberich, Kelvin Sham, Leslie P. Miranda, Shu-Chen Lu, Murielle M. Veniant-Ellison, Shanaka Stanislaus, Junming Yie, Jing Xu
  • RNAi constructs for inhibiting ASGR1 expression and methods of use thereof
    Patent number: 10870856
    Abstract: The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: December 22, 2020
    Assignee: AMGEN INC.
    Inventors: Michael Ollmann, Yang Li, Jun Zhang, Oliver Homann, Leslie P. Miranda, Justin K. Murray, Bin Wu, Oh Kyu Yoon, John Gordon Allen, Chawita Netirojjanakul
  • RNAi Constructs for Inhibiting ASGR1 Expression and Methods of Use Thereof
    Publication number: 20190309306
    Abstract: The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.
    Type: Application
    Filed: August 25, 2017
    Publication date: October 10, 2019
    Applicant: AMGEN INC.
    Inventors: Michael OLLMANN, Yang LI, Jun ZHANG, Kaustav BISWAS, Oliver HOMANN, Leslie P. MIRANDA, Justin K. MURRAY, Bin WU, Oh Kyu YOON, John Gordon ALLEN, Chawita NETIROJJANAKUL, Yuan CHENG
  • METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING GLP-1 RECEPTOR AGONISTS CONJUGATED TO ANTAGONISTS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR)
    Publication number: 20180311372
    Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.
    Type: Application
    Filed: January 16, 2018
    Publication date: November 1, 2018
    Applicant: AMGEN INC.
    Inventors: Yuan CHENG, Chawita NETIROJJANAKUL, Jerry Ryan HOLDER, Bin WU, James R. FALSEY, Bradley J. HERBERICH, Kelvin SHAM, Leslie P. MIRANDA, Shu-Chen LU, Murielle VENIANT-ELLISON, Shanaka STANISLAUS, Junming YIE, Jing XU
  • Modified FC polypeptides, FC conjugates, and methods of use thereof
    Patent number: 9834597
    Abstract: The present disclosure provides modified Fc domains having one or more attachment moieties for attaching a heterologous functional moiety; and methods of generating the modified Fc domains. The present disclosure provides Fc conjugates; and methods of making the conjugates. The Fc conjugates are useful in various methods, which are also provided.
    Type: Grant
    Filed: September 19, 2013
    Date of Patent: December 5, 2017
    Assignee: The Regents of the University of California
    Inventors: Matthew B. Francis, Chawita Netirojjanakul
  • MODIFIED FC POLYPEPTIDES, FC CONJUGATES, AND METHODS OF USE THEREOF
    Publication number: 20150218258
    Abstract: The present disclosure provides modified Fc domains having one or more attachment moieties for attaching a heterologous functional moiety; and methods of generating the modified Fc domains. The present disclosure provides Fc conjugates; and methods of making the conjugates. The Fc conjugates are useful in various methods, which are also provided.
    Type: Application
    Filed: September 19, 2013
    Publication date: August 6, 2015
    Applicant: The Regents of the University of California
    Inventors: Matthew B. Francis, Chawita Netirojjanakul